Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry.

Fetal Medicine Unit, Department of Obstetrics and Gynaecology, Royal Free Hospital, Pond Street, London, NW3 2QG, UK.
Ultrasound in Obstetrics and Gynecology (Impact Factor: 3.14). 10/2000; 16(5):402-6. DOI: 10.1046/j.1469-0705.2000.00215.x
Source: PubMed

ABSTRACT To analyze the value of second trimester ultrasound examination among those women whose fetuses were indicated to be at low risk of chromosomal anomalies on the basis of both first trimester nuchal translucency measurement and second trimester biochemical screening.
A retrospective study of 5500 pregnancies carried out at the fetal medicine unit, Royal Free Hospital. During a period of over 3 years 5500 pregnancies underwent a first trimester scan and nuchal translucency measurement which enabled the detection of 62% (20 of 32) of all chromosomal anomalies. From the remaining pregnancies that underwent second trimester biochemical screening, 3548 were considered negative (risk < 1:250; using maternal serum free beta human chorionic gonadotrophin and alpha fetoprotein). The ultrasound markers that were examined were: shortened femur length, echogenic bowel, pyelectasis, choroid plexus cysts and echogenic intracardiac foci. The likelihood ratios for chromosomal aneuploides for each of these markers were calculated.
Of the 3548 screen negative pregnancies, 3541 (99.8%) had a normal karyotype. Seven (0.2%) fetuses had an abnormal karyotype including four (0.11%) with trisomy 21, one with trisomy 18 and two with 47XXY. Second trimester ultrasound markers were found in two of the five (40%) with severe chromosomal anomalies compared to 184 of 3541 (5.2%) with normal karyotypes. Detection of one or more ultrasound markers in a screen negative pregnancy increased the possibility of chromosomal aneuploidy and a negative ultrasound decreased the risk by a likelihood ratio of 0.6 (95% confidence interval, 0.3-1.3). The risk was considerably increased when two or more markers were detected and we would recommend karyotyping under these circumstances.
This preliminary data indicates a possible role for abnormal ultrasound markers in assessing the risk of chromosomal abnormalities in patients considered to be at low risk by nuchal translucency and serum screening. However analysis of a much larger study group will have to be conducted to assess the significance of individual markers.

  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ever since the description of Down syndrome by John Langdon Down in 1866, attempts have evolved for its screening, with considerable controversy concerning the preferred method of detection in early fetal life. Until recently, identification of women at high risk was mainly based on maternal age. Screening efficacy improved with the introduction of measuring the feto-placental hormone levels in maternal serum. Ultrasound examination then made it possible to visualize certain features of Down syndrome as early as the third month of life. These three factors provided the backbone of screening for the syndrome in the first trimester or the second trimester and, sometimes, by the integration of factors from both trimesters. These advances have complicated screening but provided patients with more options and improved evaluation prior to being offered invasive diagnostic procedures. This article reviews the different screening strategies for fetal Down syndrome as well as providing an update on its recent advances.
    Expert Review of Obstetrics &amp Gynecology 05/2008; 3(3):403-416.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Die Ultraschalluntersuchung im 2. Trimenon dient v. a. der Darstellung der fetalen Anatomie und Biometrie, somit der Kontrolle des fetalen Wachstums und damit auch der endgültigen und nicht weiter veränderbaren Terminfestlegung sowie der Beurteilung fetaler anatomischer Normalität oder Auffälligkeit. Diese Auffälligkeiten umfassen Organpathologien (z. B. Hirn-Herz-Nieren-Fehlbildungen) und Marker für Chromosomenaberrationen ohne weitere Organpathologien (z. B. echogener Herzfokus, Plexus-choroideus-Zysten), Veränderungen, die beides beinhalten können (z. B. VSD, Omphalozele, Hydronephrose) und Marker für Fehlbildungen, die kein statistisch erhöhtes chromosomales Risiko tragen (z. B. "lemon" und "banana sign"). Die Beurteilung der mütterlichen Zervix ist im 2. Trimenon weiterer Untersuchungsbestandteil. Da die fetale Anatomie und Pathologie in den letzten Jahren Thema vieler Publikationen und Fortbildungen war, soll dies hier nicht Schwerpunkt dieses Artikels sein. Vielmehr ist durch das Erstrimesterscreening eine Bewegung hin zu einem Markerscreening im 2. Trimester entstanden - deren Chancen aber auch Fallstricke aufgezeigt werden sollen. Wir setzen uns in der vorliegenden Arbeit mit dem Screening im Normalkollektiv und der Wertigkeit des Ultraschalls im Risikokollektiv auseinander. Es werden die Aussagen vorliegender Übersichtsarbeiten sowie der systematischen Reviews (Cochrane) dargestellt und kritisch beurteilt. Abstract The second trimester scan represents the sonografic demonstration of fetal anatomy and biometry and increasingly of the maternal cervix. It is the control of fetal growth - based on the first trimester scan - and the definite and final dating of the pregnancy. True fetal pathologies (i. e. brain, heart, kidney) can be found as well as marker for chromosomal anomalies (i. e. choroid plexus cysts, echogeneic heart focus) and pathologies which may represent both (exomphalos, hydronephrosis) and marker for malformations without known relationship to chromosomes (lemon- and banana-sign). The second trimester markerscreening may help to save or to cause invasive procedures especially in cases without first trimester risk assessment or suspicious hormone tests. Results of meta-analysis and systematic reviews (Cochrane) are reported and evaluated.
    Der Gynäkologe 07/2002; 35(7):628-636.